BioCryst Pharmaceuticals (NASDAQ:BCRX) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a report published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $17.00 price objective on the biotechnology company’s stock. A number of other research analysts have also recently weighed in on the stock. Royal […]
Needham & Company LLC reaffirmed their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a report published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $17.00 price objective on the biotechnology company’s stock. A number of other research analysts have also recently weighed in on the stock. Royal […]
